Silexion Therapeutics Corp (SLXN) concluded trading on Thursday at a closing price of $0.96, with 12.49 million shares of worth about $11.99 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -65.26% during that period and on May 29, 2025 the price saw a loss of about -0.41%. Currently the company’s common shares owned by public are about 8.69M shares, out of which, 7.91M shares are available for trading.
Stock saw a price change of 4.27% in past 5 days and over the past one month there was a price change of 6.67%. Year-to-date (YTD), SLXN shares are showing a performance of -52.24% which decreased to -99.02% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.57 but also hit the highest price of $122.02 during that period. The average intraday trading volume for Silexion Therapeutics Corp shares is 3.10 million. The stock is currently trading -1.48% below its 20-day simple moving average (SMA20), while that difference is up 0.30% for SMA50 and it goes to -80.89% lower than SMA200.
Silexion Therapeutics Corp (NASDAQ: SLXN) currently have 8.69M outstanding shares and institutions hold larger chunk of about 10.41% of that.
The stock has a current market capitalization of $8.35M and its 3Y-monthly beta is at 0.08. It has posted earnings per share of -$19.77 in the same period. It has Quick Ratio of 3.22 while making debt-to-equity ratio of 1.34. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for SLXN, volatility over the week remained 4.38% while standing at 3.14% over the month.
Analysts are in expectations that Silexion Therapeutics Corp (SLXN) stock would likely to be making an EPS of 0 in the current quarter, while forecast for next quarter EPS is 0 and it is 0 for next year. For the current quarter EPS, analysts have given the company a lowest target 0 which is 0 at the higher side of the target for the same. Stock’s fiscal year EPS is expected to rise by 96.51% while it is estimated to decrease by -17.39% in next year. EPS is likely to grow at an annualized rate of 63.05% for next 5-years, compared to annual growth of -286.10% made by the stock over the past 5-years.
